Edap (EDAP -3.5%) falls after missing the one available analyst EPS estimate, although revenues...

|About: EDAP TMS S.A. (EDAP)|By:, SA News Editor

Edap (EDAP -3.5%) falls after missing the one available analyst EPS estimate, although revenues beat by a slim margin and rise 23% Y/Y on "strong demand for [the company's] innovative lithotripsy product range in key global markets." CEO Marc Oczachowski says the "FDA process for Ablatherm-HIFU is on track." Profit margins fall 220 basis points Y/Y on a negative yen impact and operating expenses increase 9.7% on "continued regulatory expenses associated with the PMA filing for Ablatherm-HIFU, as well as sales and marketing investments." (PR)